IEX Stock Analysis: IDEX | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 16.566m USD | 12M Return: 21.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 145M
EPS Trend: -50.9%
Qual. Beats: 5
Rev. Trend: 67.3%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IDEX Corporation (NYSE: IEX) is a diversified industrial manufacturer headquartered in Northbrook, Illinois, operating through three reportable segments: Health & Science Technologies (HST), Fluid & Metering Technologies (FMT), and Fire & Safety/Diversified Products (FSDP). Its product portfolio spans precision fluidics, pumps, valves, flow meters, sealing solutions, laboratory and medical components, optical technologies, firefighting and rescue equipment, and precision dispensing systems for paints and colorants. The company serves customers across the United States, North America, Europe, Asia, and other international markets, and was incorporated in 1987.
The company operates a decentralized, niche specialty manufacturing model, acquiring and operating businesses that hold leading positions in focused industrial, life sciences, and safety end markets. Classified within the Industrials sector under Industrial Machinery & Components, IDEX employs a multi-platform structure designed to leverage shared engineering and operational capabilities across highly fragmented sub-markets, allowing it to serve specialized customer needs across fluid handling, life sciences, and safety equipment.
- HST segment revenue grows on biopharma and semiconductor demand
- FMT margins face pressure from industrial production slowdown
- Serial acquisitions expand portfolio across health and fluid markets
| Net Income: 507.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.63 > 1.0 |
| NWC/Revenue: 34.30% < 20% (prev 31.78%; Δ 2.52% < -1%) |
| CFO/TA 0.10 > 3% & CFO 678.4m > Net Income 507.7m |
| Net Debt (1.34b) to EBITDA (939.7m): 1.43 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.4m) vs 12m ago -1.85% < -2% |
| Gross Margin: 44.42% > 18% (prev 43.40%; Δ 1.02% > 0.5%) |
| Asset Turnover: 51.48% > 50% (prev 48.31%; Δ 3.17% > 0%) |
| Interest Coverage Ratio: 11.34 > 6 (EBIT TTM 729.4m / Interest Expense TTM 64.3m) |
| A: 0.17 (Total Current Assets 1.72b - Total Current Liabilities 506.0m) / Total Assets 6.92b |
| B: 0.67 (Retained Earnings 4.62b / Total Assets 6.92b) |
| C: 0.11 (EBIT TTM 729.4m / Avg Total Assets 6.86b) |
| D: 1.41 (Book Value of Equity 4.05b / Total Liabilities 2.87b) |
| Altman-Z'' = 5.52 = AAA |
| DSRI: 1.07 (Receivables 553.0m/482.6m, Revenue 3.53b/3.28b) |
| GMI: 0.98 (GM 43.40% / 44.42%) |
| AQI: 0.99 (AQ_t 0.69 / AQ_t-1 0.69) |
| SGI: 1.08 (Revenue 3.53b / 3.28b) |
| TATA: -0.02 (NI 507.7m - CFO 678.4m) / TA 6.92b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at USD 218.39 with a total of 625,397 shares traded. Over the past week, the price has changed by -3.46%, over one month by +0.24%, over three months by +11.14% and over the past year by +21.93%.
Current recommended Stop Loss: 209.10 (which is 4.3% or 1.8 ATR below the current price).
IDEX has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy IEX.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 238.3 | 9.1% |
P/E Trailing = 33.1095
P/E Forward = 26.5252
P/S = 4.6928
P/B = 4.0906
P/EG = 1.9147
Revenue TTM = 3.53b USD
EBIT TTM = 729.4m USD
EBITDA TTM = 939.7m USD
Long Term Debt = 1.87b USD (from longTermDebt, last quarter)
Short Term Debt = 27.5m USD (from shortTermDebt, last quarter)
Debt = 1.93b USD (from shortLongTermDebtTotal, last quarter) + Leases 27.0m
Net Debt = 1.34b USD (calculated: Debt 1.93b - CCE 586.2m)
Enterprise Value = 17.9b USD (16.6b + Debt 1.93b - CCE 586.2m)
Interest Coverage Ratio = 11.34 (Ebit TTM 729.4m / Interest Expense TTM 64.3m)
EV/FCF = 29.29x (Enterprise Value 17.9b / FCF TTM 611.4m)
FCF Yield = 3.41% (FCF TTM 611.4m / Enterprise Value 17.9b)
FCF Margin = 17.32% (FCF TTM 611.4m / Revenue TTM 3.53b)
Net Margin = 14.38% (Net Income TTM 507.7m / Revenue TTM 3.53b)
Gross Margin = 44.42% ((Revenue TTM 3.53b - Cost of Revenue TTM 1.96b) / Revenue TTM)
Gross Margin QoQ = 44.89% (prev 43.05%)
Tobins Q-Ratio = 2.59 (Enterprise Value 17.9b / Total Assets 6.92b)
Interest Expense / Debt = 3.34% (Interest Expense 64.3m / Debt 1.93b)
Taxrate = 23.77% (158.1m / 665.1m)
NOPAT = 556.0m (EBIT 729.4m * (1 - 23.77%))
Current Ratio = 3.39 (Total Current Assets 1.72b / Total Current Liabilities 506.0m)
Debt / Equity = 0.48 (Debt 1.93b / totalStockholderEquity, last quarter 4.05b)
Debt / EBITDA = 1.43 (Net Debt 1.34b / EBITDA 939.7m)
Debt / FCF = 2.19 (Net Debt 1.34b / FCF TTM 611.4m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.40% (Net Income 507.7m / Total Assets 6.92b)
RoE = 12.61% (Net Income TTM 507.7m / Total Stockholder Equity 4.03b)
RoCE = 12.37% (EBIT 729.4m / Capital Employed (Equity 4.03b + L.T.Debt 1.87b))
RoIC = 8.88% (NOPAT 556.0m / Invested Capital 6.26b)
WACC = 8.96% (E(16.6b)/V(18.5b) * Re(9.71%) + D(1.93b)/V(18.5b) * Rd(3.34%) * (1-Tc(0.24)))
Discount Rate = 9.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -71.49 | Cagr: -1.18%
[DCF] Terminal Value 74.56% ; FCFF base≈590.0m ; Y1≈639.5m ; Y5≈789.3m
[DCF] Fair Price = 129.5 (EV 10.9b - Net Debt 1.34b = Equity 9.59b / Shares 74.0m; r=8.96% [WACC]; 5y FCF grow 9.61% → 2.50% )
EPS Correlation: -50.87 | EPS CAGR: -1.75% | SUE: 4.0 | # QB: 5
Revenue Correlation: 67.28 | Revenue CAGR: 2.37% | SUE: 3.07 | # QB: 3
EPS current Quarter (2026-06-30): EPS=2.11 | Chg30d=+0.02% | Revisions=+50% | Analysts=13
EPS next Quarter (2026-09-30): EPS=2.19 | Chg30d=+0.06% | Revisions=+15% | Analysts=13
EPS current Year (2026-12-31): EPS=8.50 | Chg30d=+0.00% | Revisions=+80% | GrowthEPS=+6.9% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=9.23 | Chg30d=+0.32% | Revisions=+57% | GrowthEPS=+8.6% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +62% (up=31, down=6)